Article ID Journal Published Year Pages File Type
2779573 Bone 2012 8 Pages PDF
Abstract

Saracatinib (AZD0530) is an orally active once-daily Src kinase inhibitor which modulates key signaling pathways in cancer cells. In a Phase I study in patients with advanced solid malignancies resistant to standard treatment we assessed the effect of saracatinib on bone turnover.Fifty-one patients were randomized into three parallel groups to receive saracatinib 50, 125 or 175 mg/day. After a single dose followed by a 7-day washout, patients received once-daily doses for 21 days. Bone turnover markers were measured in serum and urine samples collected before dosing on days 1, 2, 3, 17 and 28.Samples were available at baseline and more than one other time point for 44 patients. Bone resorption markers were significantly decreased by saracatinib. Serum cross-linked C-terminal telopeptide of type I collagen (sCTX) changed in the 50, 125 and 175 mg/day groups by -36% (95% CI -58, -4), -64% (95% CI -75, -48) and -75% (95% CI -83, -61), respectively, at day 28. Urinary cross-linked N-terminal telopeptide of type I collagen/creatinine ratio (uNTX/Cr) changed in the 50, 125 and 175 mg/day groups by; -13% (95% CI -33, 13), -48% (95% CI -59, -34) and -50% (95% CI -62, -35), respectively, at day 28.The significant decreases in bone resorption markers indicate that suppression of Src kinase inhibits osteoclast activity in patients with advanced cancer. This result suggests that saracatinib may have therapeutic benefit in metastatic bone disease.

► Saracatinib significantly decreased bone resorption markers in advanced cancer. ► Suppression of Src kinase by saracatinib appears to inhibit osteoclast activity. ► Type I collagen degradation products significantly decreased with increasing dose. ► Anemia, nausea and anorexia were the most common AEs. ► Asthenia, constipation, fatigue and vomiting were also seen in ≥ 20% of patients.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Developmental Biology
Authors
, , , , , , , ,